• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Isofol Medical

0.71 SEK

+5.03 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.03 %
-2.34 %
+12.70 %
-2.61 %
+1.43 %
-27.59 %
+48.80 %
-91.07 %
-94.73 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Read more
Market cap
227.55M SEK
Turnover
169.31K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

12.2.
2027

Annual report '26

Regulatory press release5/19/2026, 2:45 PM

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

Isofol Medical
Press release5/19/2026, 11:14 AM

Redeye: Isofol Medical (Q1 Review): Tailwind despite slower recruitment

Isofol Medical
Third party research5/19/2026, 7:38 AM

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Isofol Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/19/2026, 6:00 AM

Isofol Medical AB (publ) publishes interim report, January – March 2026

Isofol Medical
Regulatory press release4/30/2026, 6:00 AM

New number of shares and votes in Isofol

Isofol Medical
Regulatory press release4/15/2026, 2:00 PM

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol Medical
Press release4/15/2026, 7:10 AM

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical
Regulatory press release4/10/2026, 6:00 AM

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Isofol Medical
Regulatory press release3/31/2026, 3:00 PM

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol Medical
Regulatory press release3/18/2026, 12:50 PM

Isofol secures license rights for arfolitixorin in autism

Isofol Medical
Regulatory press release3/13/2026, 5:40 PM

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol Medical
Regulatory press release3/11/2026, 2:30 PM

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol Medical
Regulatory press release3/9/2026, 10:00 AM

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol Medical
Press release3/3/2026, 7:30 AM

Isofol presents at investor meetings in March

Isofol Medical
Third party research2/25/2026, 6:22 AM

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Isofol Medical
Regulatory press release2/24/2026, 8:32 AM

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Isofol Medical
Press release2/19/2026, 8:36 AM

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical
Regulatory press release2/18/2026, 6:30 AM

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical
Third party research1/15/2026, 12:46 PM

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Isofol Medical
Press release1/9/2026, 6:30 AM

Isofol participates in the ASCO GI congress

Isofol Medical